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CD47Fibrinogen is a multifunctional plasma protein that plays a crucial role in several biological processes. Elevat-
ed ﬁbrinogen induces erythrocyte hyperaggregation, suggesting an interaction between this protein and red
blood cells (RBCs). Several studies support the concept that ﬁbrinogen interacts with RBC membrane and this
binding, due to speciﬁc and non-speciﬁc mechanisms, may be a trigger to RBC hyperaggregation in inﬂamma-
tion. The main goals of our work were to prove that human RBCs are able to speciﬁcally bind soluble ﬁbrin-
ogen, and identify membrane molecular targets that could be involved in this process. RBCs were ﬁrst
isolated from blood of healthy individuals and then separated in different age fractions by discontinuous Per-
coll gradients. After isolation RBC samples were incubated with human soluble ﬁbrinogen and/or with a
blocking antibody against CD47 followed by ﬂuorescence confocal microscopy, ﬂow cytometry acquisitions
and zeta potential measurements. Our data show that soluble ﬁbrinogen interacts with the human RBC mem-
brane in an age-dependent manner, with younger RBCs interacting more with soluble ﬁbrinogen than the
older cells. Importantly, this interaction is abrogated in the presence of a speciﬁc antibody against CD47.
Our results support a speciﬁc and age-dependent interaction of soluble ﬁbrinogen with human RBC mem-
brane; additionally we present CD47 as a putative mediator in this process. This interaction may contribute
to RBC hyperaggregation in inﬂammation.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Fibrinogen is amultifunctional proteinwith 340 kDa, synthesized by
hepatocytes and secreted into the bloodstream. It consists in two sets of
three distinct polypeptide chains:α (610 aa),β (461 aa) andγ (411 aa).
In physiological conditions, ﬁbrinogen circulates at concentrations
ranging from 2 to 4 mg/mL Fibrinogen is a component of the coagula-
tion cascade as well as a determinant in plasma viscosity and erythro-
cyte aggregation [1–5]. Recently the role of ﬁbrinogen has been
expanded beyond its hemostatic and hemorheological functions. It
was demonstrated to be an acute phase protein mediating various pro-
cesses involved in inﬂammation. Several biological responses occur
due to its ability to affect and bind to cells involved in the inﬂammatory
process. For such, ﬁbrinogen displays binding sites for unique and very
speciﬁc cellular receptors expressed by these cells [3,5].d Inﬂammation Unit, Institute




rights reserved.Under inﬂammatory conditions ﬁbrinogen synthesis is upregulated.
This increase in plasma ﬁbrinogen levels affects hemorheological pa-
rameters such as red blood cell aggregation, blood viscosity and conse-
quently interfereswith blood ﬂow [4,6,7]. Additionally, elevated plasma
ﬁbrinogen levels are a major independent cardiovascular risk factor [8].
This protein is also considered as a “non-speciﬁc glue” leading to in-
creased adhesiveness/aggregation of both Red Blood Cells (RBCs) and
leukocytes [7].
RBCs represent the largest group of cellular elements of blood, and
therefore these cells signiﬁcantly inﬂuence blood ﬂow and its rheolo-
gy. RBC deformability and aggregation are its major characteristics
that modulate microvascular hemorheology [9]. RBC aggregates are
responsible for excluding leukocytes from the bulk suspension induc-
ing their interaction to the endothelium, promoting their migration
and thus favoring inﬂammation [8]. Erythrocyte hyperaggregation oc-
curs in diabetes, atherosclerosis, arterial hypertension, ischemic heart
disease, stroke and other vascular pathologies [4,5,10,11]. Inhibition
of erythrocyte aggregation can prevent and reduce the overall throm-
boembolic risk [12].
Since elevated ﬁbrinogen induces RBCs hyperaggregation, this
suggests that it interacts with the erythrocyte membrane. Fibrinogen
Aα chain has been proposed as a binding site responsible for this in-
teraction [13,14]. Lominadze et al. [15], using murine RBCs and
ghosts, suggested that soluble ﬁbrinogen binds to the erythrocyte
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could trigger RBC hyperaggregation in inﬂammation. They also pro-
pose that this interaction could be Arginine–Glycine–Aspartate
(RGD) peptide dependent [15]. More recently, Carvalho et al.
reported, in two different works [16,17], using atomic force microsco-
py (AFM) as main technique, the existence of a single-molecule inter-
action between ﬁbrinogen and an unknown receptor on the RBC. In
the ﬁrst work [16], Carvalho et al.'s main conclusion was that this re-
ceptor is anαIIbβ3-related integrin. The second work [17] is focused in
the variations on ﬁbrinogen binding to RBC membrane during the cell
aging, showing that younger RBCs bind more to ﬁbrinogen than the
older ones. This aspect will be explored in detail in our study
Erythrocyte membrane surface have several molecular targets that
could act as receptor/target for soluble ﬁbrinogen such as the
integrin-associated protein (IAP) or CD47, integrin cell adhesion
molecule-4 (ICAM-4), basal cell adhesion molecule (BCAM/LU),
CD147, CD44, CD58, and glycosphingolipids (gangliosides). All these
molecules are essential in erythropoiesis and some are also important
during erythrocyte clearance from the bloodstream [18–20]. More-
over, developments in proteomic ﬁeld also have made possible to
perform complex analysis of membrane proteome from RBCs given
us a more accurate knowledge from RBCs membrane content [21,22].
Although ﬁbrinogen–erythrocyte interaction has been properly
established, we think that there were several aspects that needed to
be clariﬁed. In summary, we report that there are not enough data to
support the idea that soluble ﬁbrinogen–human erythrocyte interaction
is integrin dependent but it is undoubtedly age dependent. Additionally,
we also propose CD47 as a putative mediator for this binding.
2. Materials and methods
2.1. Chemical reagents
K3EDTA tubes from Vacuette-Greiner Bio One (Austria), NaCl
(S7653), CaCl2.2H20 (22350-6), MgSO4.7H20 (63140), MgCl2.6H20
(M9272), Percoll (P-1644), Albumin (A-2153), Poly-L-lysine P-9404,
Fibrinogen fraction I, type I from human plasma (F-3879), Arginine–
Glycine–Aspartate (RGD) peptide (A 8052) and Arginine–Glycine–As-
partate–Serine (RGDS) (A 9041) from Sigma-Aldrich (US). Hank's
Balance Salt Solution without calcium or magnesium (iHBSS)
(14175-129) from Gibco-Invitrogen (US). Antibodies against glyco-
phorin A (αGPA) (PE) (12-9987) conjugated with Phycoeryithrin
(PE) and CD41 conjugated with Fluoresceine isothiocyanate (FITC)
(11-0411-81) from eBioscience (US). Human ﬁbrinogen conjugated
with Alexa 488 (Fib-Alexa488) (F-13191), human ﬁbrinogen conju-
gated with Alexa 647 (Fib-Alexa647) (F-35200), and calcein-AM (C-
1430) from Invitrogen-Molecular Probes (US). Antibody against
CD47 (αCD47) conjugated with Phycoeryithrin (556046) from BD
Biosciences Pharmigen (US).
2.2. Blood collection and RBC isolation
Human blood samples were obtained by vein puncture from healthy
volunteer donors at the public blood bank Instituto Português do Sangue
(Lisbon, Portugal) under an institutional agreement with the Instituto
de Bioquímica from Faculdade de Medicina da Universidade de Lisboa.
Donors were informed and written consent was signed. This study
was approved by the Ethics Committee of Faculdade de Medicina da
Universidade de Lisboa. Donors were asked to give up to 9 mL of blood
for research purposes additionally to their common blood donation of
450 mL to the blood bank. The blood collection was made anonymously
as the data treatment resulting from the experiences made with these
samples. The samples were drawn to K3EDTA anticoagulant tubes.
Brieﬂy, a centrifugation was carried out at 200g for 15 min at 20 °C
in a refrigerated centrifuge from Heraeus (United Kingdom), to ﬁrst
remove the plasma rich in platelets and the buffy coat. Then RBCswere washed three times with a solution of 0.9% NaCl at 2000 g for
periods of 5 min at 20 °C. Packed RBCs were resuspended at a ﬁnal
concentration of 4–5×109RBC/mL with HEPES isotonic saline buffer:
133 mM NaCl, 4.5 mM KCl, 10 mM HEPES, pH 7.4.
2.3. Percoll discontinuous gradient
Human RBCs of different biological age, from healthy donors were
separated as described by Corsi et al.and Venerando et al.[23,24] with
some modiﬁcations. Brieﬂy, the following solutions were prepared at
room temperature (RT): HEPES-buffered stock solution (HBS stock):
2.66 M NaCl, 0.09 M KCl, 0.2 M HEPES, pH 7.4; solution A (BSA-
HEPES-buffered solution, pH 7.4): 19 volumes of 5.25% (w/v) BSA in
water solution added to 1 volume of HBS-stock solution; solution B
(BSA-Percoll-HEPES-buffered solution, pH 7.4): 19 volumes of 5.25%
(w/v) BSA in Percoll added to 1 volume of HBS-stock solution. Solu-
tions A and B were mixed to form 5 solutions at ﬁnal Percoll concen-
trations of 60%, 66%, 70%, 74%, and 80% (vol/vol; density 1.087–
1.098 g/mL, pH 7.4). Discontinuous 5-step gradients were prepared
by over layering 0.360 mL of 80%, 2.9 mL of 74%, 2.9 mL of 70%,
2.9 mL of 66%, and 1.46 mL of 60% of Percoll concentration in 15 mL
tubes. A centrifugation was carried out at 2700g for 30 min at 20 °C
to prepare de gradient. Next 1.46 mL of 4–5×109RBC/mL was layered
on the top of the gradient and centrifugation was carried out at 2700g
for 40 min. All the centrifugations were slowly decelerated over
3 min to prevent gradient disturbance. The plasma remaining above
the gradient was removed, and cell fractions were collected manually
over the liquid interface by aspiration from the top of the gradient
using a Pasteur pipette. The fractions containing the young cells con-
centrated in the upper layer (over 60%), the average age cells layered
over 66% and 70%, and the fractions containing the senescent cells
layered over 74% were pooled carefully with a syringe and washed
3 times with HEPES-buffered isotonic saline at 2700g for 5 min at
20 °C. The age-dependent separation of RBCs into different fractions
was conﬁrmed by the determination of mean cell volume and mean
cell haemoglobin with a cell counter (CellDyn 1600 from Abbott Lab-
oratories). To assess that RBCs were being properly separated by this
method, calcein-AM was used to conﬁrm cell aging and viability of
different fractions. Samples of total young and aged RBC were resus-
pended at a ﬁnal concentration of 1×107RBC/mL with a solution of
HBSS with 2%BSA pH7.4. In order to simplify from this point on
total RBC will be called as RBC_T, young RBC will be called as RBC_Y
and aged RBC will be called as RBC_O.
2.4. Sample preparation for ﬂow cytometry
To study ﬁbrinogen interaction with RBCs, these were labeled ﬁrst
with antibodies (according to manufacturer) and peptides (2.5 mM)
for 15 min at RT in the dark. Samples were washed 2 times with
iHBSS centrifugations were carried out at 1500g for 5 min at RT. RBC
samples were resuspended at a ﬁnal concentration of 1×107RBC/mL
with HBSS pH 7.4. The different RBC populations were incubated with
human ﬁbrinogen (Alexa488- or Alexa647-labeled) (1 mg/mL) for
15 min at RT in the dark. Cellswere resuspended at aﬁnal concentration
of 1×106RBC/mLwith iHBSS pH7.4 at 4 °C, and placed in ice. Flow cyto-
metry analyses were made in a FACSCalibur analyzer from Beckman
(Germany). Settings were obtained and maintained constant through-
out the experiments. Data were analyzed with the software Flow Jo.
2.5. Sample preparation for confocal microscopy
RBCs were labeled with calcein 10 μM for 45 min at 37 °C in the
dark, then samples were washed two times with HBSS 2%BSA at
1500 g, 5 min at RT and resuspended 1×107RBCs/mL with HBSS
2%BSA. Next RBCs were labeled with antibodies and peptides for
15 min at RT in the dark, the samples were washed again two times
Fig. 1. Fluorescence confocal microscopy of isolated human RBC. (A and B) Human RBC
were labelled with human soluble ﬁbrinogen conjugated with Alexa488 (green signal)
and/or an antibody against glycophorin A (GPA) conjugated with Phycoeryithrin (PE)
(αGPA (PE)) (red signal). (A) 3D projection of ﬂuorescent confocal microscopy images
of isolated human RBC binding ﬁbrinogen–Alexa488 (scale bar=7 μm). Fibrinogen
binding seems to occur in speciﬁc points of RBC membrane. (B) Fluorescent confocal
microscopy image of isolated human RBC double labelled with ﬁbrinogen–Alexa488
(green signal) and an anti-GPA antibody (red signal) that was used as a RBC marker
(scale bar=10 μm). We can observe that not all RBC are double labelled (yellow signal).
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tion 1×107RBCs/mL The different RBC populations were incubated
with human ﬁbrinogen–Alexa 647 (1 mg/mL) for 15 min at RT in
the dark, and centrifuged at 1500g for 5 min at RT to remove free
Fib-Alexa647. Cells were resuspended with HBSS 1%BSA at
1×106RBCs/mL and 50 μL of cell suspension was left to adhere to
poly-L-lysine pre-coated cover-slips for 15 min at RT in the dark.
The cover-slip was then mounted in slides using HBSS 1%BSA as a
mount medium, and sealed with nail polish.
In a different experiment the RBCswere only labeledwithﬁbrinogen–
Alexa488 orwith anti-GPA antibody and ﬁbrinogen–Alexa488,maintain-
ing the overall experimental procedure.
Fluorescence images were taken in a confocal microscope Zeiss
LSM 510Meta from Zeiss (Germany) using an Argon/2, DPSS 561-10
and HeNe633 lasers and a 63× Plan-Apochromatic oil immersion ob-
jective. Laser and detector settings were constant within the same ex-
periments. Images were analyzed in the computer program Image J.
2.6. Zeta-potential measurements
Zeta-potential (ζ) measurements were made in RBCs samples as
described by Carvalho et al.[17], with some minor modiﬁcations.
Brieﬂy, measurements were conducted on a dynamic light scattering
and zeta-potential equipment Malvern Zetasizer Nano ZS (Malvern,
UK), equipped with a He–Ne laser (λ=632.8 nm). The zeta-
potential of the samples were determined, at 25 °C, from the mean
of 15 measurements, with 50 runs each, with an applied potential of
30 V. The measurements were made in RBC samples pre-incubated
or not with an antibody against CD47, in the absence or presence of
different soluble human ﬁbrinogen concentrations, using disposable
zeta cells with platinum gold-coated electrodes (Malvern). The elec-
trophoretic mobility obtained was used for the zeta-potential calcula-




where u represents the electrophoretic mobility, η the viscosity of the
solvent and ε its dielectric constant. The variation of the zeta-
potential (Δζ) for each sample was calculated by subtracting from
the zeta-potential value of the sample the initial value corresponding
to zero ﬁbrinogen concentration. These differences can be plotted as a
function of ﬁbrinogen concentration, and the experimental data ﬁtted
using the equation [26,27]
Δζ ¼ ΔζmaxKL Fibrinogen½ 
1þ KL Fibrinogen½ ð Þ
ð2Þ
where Δζmax is the maximum amplitude of variation of the zeta-
potential induced by the interaction with ﬁbrinogen, and KL corre-
sponds to the inverse of the value of ﬁbrinogen concentration at
ζmax/2.
2.7. Statistics
Flow cytometry data were statistical analyzed in Graph Prism 5.
The three different populations of RBC (Geometric Mean and Median)
were assessed by One or TwoWay ANOVA. Signiﬁcance was accepted
for a P value less than 0.05.
3. Results
3.1. Fibrinogen interaction with erythrocytes
Human ﬁbrinogen interaction with RBCmembrane was studied by
laser ﬂuorescence confocal microscopy and ﬂow cytometry. In Fig. 1we show ﬂuorescence confocal images that were taken from isolated
erythrocytes labeled with ﬁbrinogen–Alexa 488 (green signal)
(Fig. 1A and Suppl. M1) or double labeled with an antibody against
the RBC marker glycophorin A (GPA) and ﬁbrinogen–Alexa 488
(Fig. 1B). These images show that soluble ﬁbrinogen interact with
RBCs membranes in a discrete punctuated pattern. Accordingly, we
were also able to detect and quantify the interaction between soluble
ﬁbrinogen and RBCs membrane by using ﬂow cytometry (Fig. 2A).
3.2. Fibrinogen interaction with erythrocytes is αIIbβ3 integrin and RGD/
RGDS independent
Following description of the soluble ﬁbrinogen binding with RBCs,
we also decided to check if this interaction of ﬁbrinogen with RBCs
was promoted by the presence of the known ﬁbrinogen receptor
the αIIbβ3 , For that we used a FITC-labeled antibody against CD41, a
commonly used platelet marker that associates to CD61 forming the
αIIbβ3 integrin receptor. Our data show that RBCs from whole
blood samples did not stain for CD41 (Fig. 2). Next we addressed
whether soluble ﬁbrinogen binding to RBCs was occurring due to an
integrin related receptor, by using peptides Arginine–Glycine–Aspar-
tate (RGD) and Arginine–Glycine–Aspartate–Serine (RGDS) in a com-
petition study, a commonly used method to study ﬁbrinogen
interaction with integrin-like receptors [15]. Our data indicate that
the presence of peptides RGD or RGDS did not signiﬁcantly affect
the interaction of RBCs with soluble ﬁbrinogen (Fig. 3).
3.3. Age dependency of ﬁbrinogen interaction with erythrocytes
In the microscopy experiments, we noticed that not all RBCs were
able to bind ﬂuorescently labeled ﬁbrinogen with similar intensity
(Fig. 1B). This fact led us to hypothesize that interaction with soluble
ﬁbrinogen might be dependent on the RBC age. In this respect, we in-
vestigated ﬁbrinogen binding to RBC populations with different ages.
The positive labeling with anti-GPA antibody (αGPA) was used to
facilitate the identiﬁcation of three different populations of RBCs in
ﬂow cytometry experiments: (i) total RBCs designed as RBC_T
(Fig. 4A), (ii) young RBCs as RBC_Y (Fig. 4B), and (iii) old RBCs
Fig. 2. Flow cytometry of whole human blood. Subpopulations of Platelets and RBC were labelled with an anti-CD41 (FITC) and anti-GPA (PE) respectively. For each subpopulation
we performed SSC/FSC as well as CD41 (FITC) /αGPA (PE) plots. As expected our data show clearly that CD41 (FITC) positive labelling was presented in platelet population (99.7%)
and GPA (PE) in RBC population (99.5%). A very small percentage (0.2%) shows a positive labelling both for CD41 and GPA in RBC gated population, which could be due to some
platelets aggregated to RBCs.
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bodies against GPA promote RBC agglutination (notice the dispersion
of different RBCs populations in SSC/FSC plots as well as the formation
of smallest peaks in the ﬂuorescence histogram for αGPA (Fig. 5A),
thus we limited its utilization to initial setup experiments.Fig. 3. Flow cytometry histogram and analysis from isolated human RBCs labeled with Fib
Alexa488-RGD, RBC_Fib Alexa488-RGDS and RBC_Fib Alexa488. The interaction with human
of RGD or RGDS. (B) Analysis of geometric mean and median values for the different sample
RGD and RGDS.Nevertheless, we found that RBC agglutination was not detrimental
towards binding of soluble ﬁbrinogen with erythrocytes.
Calcein-AMwas used to conﬁrm the age and viability of the differ-
ent RBC populations separated by the Percoll discontinuous gradient.
This probe is a highly lipophilic vital dye that passively enters viable-Alexa488 in presence of RGD and RGDS. (A) Flow cytometry histograms for RBC_Fib
soluble ﬁbrinogen was not signiﬁcantly affected (P>0.05) neither due to the presence
s. The interaction of soluble Fib-Alexa488 with RBC was not affected in the presence of
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duces an intense green signal, cells with intact plasma membrane
are able to retain this probe [30]. As shown in supplemental ﬁgure
S2, calcein ﬂuorescence in young RBCs was higher than that in old
RBCs due to the increased esterase activity, which means that Percoll
discontinuous gradient is a good method to separated RBCs according
to age.
In ﬂow cytometry (Fig. 5A), we observed that ﬁbrinogen interacts
more with young RBCs than with older RBCs. The geometric mean
and median of ﬂuorescence (Fig. 5B) were statistically analyzed and
conﬁrm that ﬁbrinogen interaction with young RBCs is signiﬁcantly
higher (Pb0.01) than with aged RBCs.
Next we made use of ﬂuorescence confocal microscopy to test our
working hypothesis. In Fig. 6A we present images taken from the
three different populations of RBCs labeled with calcein (blue signal)
and ﬁbrinogen–Alexa647 (red signal). We can observe a higher inter-
action of ﬁbrinogen–Alexa 647 with RBC_Y subpopulation than with
RBC_T, and importantly notice the absence of ﬁbrinogen–Alexa 647
labeling in the RBC_O subpopulation (Fig. 6A).
3.4. CD47 mediates differential binding of soluble ﬁbrinogen to younger
and old erythrocytes
The differential binding of soluble ﬁbrinogen to subpopulations of
erythrocytes led us to look closer at membrane proteins involved in
erythrocyte survival and removal from the circulation. From several
potential targets CD47 was an obvious one, since it is directly in-
volved in these processes [31,32].
The role of CD47 in the interaction of the erythrocyte membrane
with soluble ﬁbrinogen was studied by ﬂow cytometry of different
RBCs populations (Fig. 7A). For this experiment erythrocytes were
previously incubated with an antibody against CD47 (αCD47), before
ﬁbrinogen–Alexa488 addition. As published by others, this antibody
also promotes RBC agglutination [33,34]. We conﬁrmed this with
the same strategy that we previously used for anti-GPA, by observing
the dispersion of the different RBC subpopulations in SSC/FSC plots
(data not shown) as well as the formation of smallest peaks in histo-
gram for αCD47 (Fig. 7A). RBCs with different biological ages have
shown to have similar CD47 levels (Fig. 7A).
Strikingly, the interaction of soluble ﬁbrinogen with the RBC
membrane is signiﬁcantly decreased by blocking CD47 in its surface.
The ﬂow cytometry experiments reveal that the interaction of soluble
ﬁbrinogen–Alexa 647 with RBC membrane is diminished in all sam-
ples and much more evident for the case of the younger RBCs
(Fig. 7A). In the presence of the anti-CD47 antibody the ﬁbrinogen–
Alexa 647 binding becomes similar for all the three samples. Appar-
ently young RBCs lose their ability to bind more soluble ﬁbrinogen
than other RBCs subpopulations when we block CD47. Flow cytome-
try control experiments with isotype antibodies for αCD47 and
αGPA were made (Suppl. S3).
We also obtained ﬂuorescence confocal microscopy images of
RBCs pre-incubated with αCD47, and then with ﬁbrinogen–
Alexa647 (Fig. 6B). In the presence of anti-CD47 antibody we ob-
served no evidence of binding of soluble ﬁbrinogen–Alexa647 to
any of the RBCs subpopulations indicating that this anti-CD47 anti-
body is acting as a blocker for ﬁbrinogen–Alexa647 binding to the
erythrocyte membrane.
To conﬁrm our previous data we decided to make use of a differ-
ent type of approach, so we performed zeta-potential measurements
in RBCs pre-incubated with the anti-CD47 antibody in absence or
presence of 1 and 3 mg/mL of human soluble ﬁbrinogen. The zeta-
potential measurements show us once more that the presence of
the anti-CD47 antibody diminishes the ability of young blood cells
to bind soluble ﬁbrinogen, reaching a similar level observed for the
old RBCs. The extension of the ﬁbrinogen–young RBCs interaction
obtained, Δζmax=(7.4±1.4) mV, is signiﬁcantly higher (Pb0.001)than the values obtained for young RBCs in the presence of anti-
CD47 Δζmax=(3.5±0.8) mV, old RBCs Δζmax=(2.5±1.2) mV and
old RBCs in the presence of anti-CD47 Δζmax=(2.4±1) mV (Fig. 8).
4. Discussion
It has been previously proposed that RBC hyperaggregation may
occur as a result of soluble ﬁbrinogen binding that would take place
due to non-speciﬁc and speciﬁc mechanisms [13–17]. Some studies
actually point out that ﬁbrinogen alpha chain might be the possible
binding site of this molecule to RBC membrane [13,14]. Additionally,
recent studies using biophysical approaches have tried to better un-
derstand the possible ﬁbrinogen–erythrocyte interaction [16,17]. Al-
though we agree that soluble ﬁbrinogen may interacts non-
speciﬁcally and speciﬁcally with erythrocyte membranes, from our
point of view these studies needed to be complemented and clariﬁed
by a different approach, so we tried to elucidate this issue by develop-
ing a simple and fresh strategy mainly based on in situ experiments
and molecular cell biology methodologies. Our main goals were to
prove that human RBCs are able to speciﬁcally bind soluble ﬁbrino-
gen, and additionally identify membrane molecular targets that
could be involved in this process. So, we have used a set of experi-
ments that include ﬂow cytometry and ﬂuorescence confocal micros-
copy methodologies, in order to quantify and image (for the ﬁrst
time) the soluble ﬁbrinogen–erythrocyte interaction, and to support
our ﬁndings we also have used zeta-potential measurements, as a
biophysical approach that was recently established and published
by Carvalho et al. [17] to study this theme.
Platelets and platelet-microparticules are enriched inαIIbβ3, awell-
known and studied receptor of soluble ﬁbrinogen. Furthermore, the
presence of platelets or platelet microparticules (MP) adhered to RBCs
membrane is possible in circulation. So, to address whether ﬁbrino-
gen–erythrocyte interaction is not occurring as a result of αIIbβ3 due
to its presence in RBCs-platelets or platelets MP aggregates, we used
CD41 immunostaining to perform ﬂow cytometry measurements
(CD41 is a commonly used plateletmarker and indicator of glycoprotein
αIIbβ3 presence). Our data showed no evidence for the presence of this
platelet speciﬁc- integrin in the RBCs population. So these results, to-
gether with the ﬂuorescent confocal microscopy images (Fig. 1A,
Suppl. S4 andM1),madeus to conclude that theﬁbrinogen–erythrocyte
interaction is not occurring due to αIIbβ3 presence from aggregated
platelets or platelet-microparticules to the RBCs membrane.
Lominadze et al. [15] using murine RBCs and ghosts, reported that
ﬁbrinogen binding to RBCs membrane and aggregation due to its
presence, was blocked by Arginine–Glycine–Aspartate–Serine
(RGDS) peptide, which indicated that the speciﬁc binding of ﬁbrino-
gen to RBCs could occur due to an integrin-like receptor. Additionally,
Carvalho et al. [16] compares the ﬁbrinogen–platelet interaction with
the ﬁbrinogen–erythrocyte interaction in her AFM study. This study
starts to report that the receptor should be αIIbβ3-like because,
according to their data, this interaction was not so strongly inﬂuenced
by calcium and eptiﬁbatide (a speciﬁc inhibitor of αIIbβ3). At the end
they claimed that it as to be a related β3 integrin-like receptor, sup-
porting their ﬁndings in just one case from a patient with Glanzmann
thrombasthenia (a rare hereditary bleeding disorder caused by a
αIIbβ3 deﬁciency) that had a mutation in β3 subunit. Notice that the
atomic force microscopy approach employed in the mentioned
study uses tips coated with adsorbed ﬁbrinogen; since adsorbed ﬁ-
brinogen changes its conformation and exposes previously hidden
epitopes, interaction reports from adsorbed ﬁbrinogen may not be a
faithful representative of the interactions established by the soluble
molecule. Both studies report [15,16] that speciﬁc soluble ﬁbrino-
gen–erythrocyte interaction occurs due to an integrin-like receptor,
so it should be Arginine–Glycine–Aspartate (RGD) and Arginine–Gly-
cine–Aspartate–Serine (RGDS) dependent. These two sequences are
located at ﬁbrinogen alpha chain and both are responsible for the
486 S. De Oliveira et al. / Biochimica et Biophysica Acta 1818 (2012) 481–490
Fig. 5. Analysis of ﬂow cytometry from RBC labelled with Fib-Alexa488 and/or αGPA (PE). (A) Flow cytometry histograms for Total RBC (RBC_T), Young RBC (RBC_Y) and Old RBC
(RBC_O), labelled with Fib-Alexa488 and/or αGPA (PE). The interaction with human soluble ﬁbrinogen was signiﬁcantly higher (Pb0.01) in RBC_Y than in the other two RBC sub-
populations (*Pb0.01). (B) Analysis of geometric mean and median values for the different RBC subpopulations labelled with Fib-Alexa488 and/or αGPA (PE). Signiﬁcant different
values for geometric mean and median (Pb0.01) are found between the interaction of soluble Fib-Alexa488 with young RBC and with old RBC. Notice that there were no signiﬁcant
differences between RBC+Fib-Alexa488 and RBC+Fib-Alexa488+αGPA, which shows that αGPA(PE) does not interfere with ﬁbrinogen interaction with RBC membrane.
487S. De Oliveira et al. / Biochimica et Biophysica Acta 1818 (2012) 481–490low intensity interaction with integrin-like receptors. Our results in-
dicate that the presence of peptides RGD/RGDS do not inhibit the sol-
uble ﬁbrinogen binding to human RBCs neither the erythrocyte
aggregation (data not shown), contrary to what it was reported by
Lominadze et al. using murine RBCs/ghosts [15]. So, according to
this there are no data to support the idea that soluble ﬁbrinogen spe-
ciﬁc binds to RBCs as a result of an integrin-like receptor.
As we mentioned before the interaction between soluble ﬁbrino-
gen and RBC membrane was already studied and veriﬁed by others,
although we present for the ﬁrst time ﬂuorescent confocal microsco-
py images of it. From the beginning we noticed that this interaction
seems to occur in speciﬁc points of the membrane, and that not all
RBCs appear to be able to equally bind ﬁbrinogen. This fact had led
us to hypothesize that the variations on ﬁbrinogen–erythrocyte inter-
actions could be age dependent. Knowing that the isoelectric point of
ﬁbrinogen is around 5.1–5.5, being negatively charged under physio-
logical conditions (pH 7.4), and also that aged RBCs have a less nega-
tively charged membrane [35,36] consequently with an higher
aggregation index [7,11,15,17,37–40], we expected that ﬁbrinogen
would interact more with old RBCs in comparison with the young
ones. But surprisingly the opposite occurs. All our approaches have
conﬁrmed that soluble ﬁbrinogen interacts more extensively with
younger RBCs than with the old ones, suggesting that erythrocyte
binding afﬁnity for ﬁbrinogen is surpass but not dependent of RBC
membrane external charge (Figs. 5, 6A and 8). So our data conﬁrm
the recently published idea that ﬁbrinogen–erythrocyte interaction
is age-dependent [17].Fig. 4. Flow cytometry of isolated human RBC with different biological ages. Subpopulat
Alexa488). For each RBC subpopulation we performed SSC/FSC as well as αGPA (PE)/Fib-A
(C). In each set of data the ﬁrst and second column are controls for single stainings of eac
plots) shows double positive labelled RBC with Fib-Alexa488 and αGPA (PE). All RBC sub
the SSC/FSC plots we observe that the anti-GPA antibody (second and third column) increa
the formation of RBC duplets and triplets.All the data collected until this point prompted us to further eval-
uate the possibility for the existence of a speciﬁc molecular target at
the RBCs membrane for soluble ﬁbrinogen. Actually, RBCs have a
wide range of surface molecules that could be responsible for this in-
teraction such as CD47, B-CAM, VLA-4 and glycosphingolipids (gan-
gliosides) [18,19,41–43]. From all these targets, CD47 was a very
strong candidate due to several characteristics. For example, in RBCs
this integrin-associated protein is involved in diverse biological func-
tions, it is part of the Rh macrocomplex which is connected to the cy-
toskeleton via protein 4.2, and interacts also with the major
erythrocytic macrocomplex Band 3 that among other functions is in-
volved in RBC aggregation [44–47]. CD47 is also a molecular target for
several proteins such as thrombospondin, laminin, and ﬁbronectin
[48,49]. Besides all this, CD47 is implicated in erythrocyte clearance
by phagocytes. On healthy cells CD47 binds to the tyrosine kinase sig-
nal regulatory protein α (SIRPα) [45,46,50,51], this engagement is a
key “don't eat me” signal from healthy cells to phagocytes [50].
RBCs are cleared from the bloodstream mainly in the spleen by splen-
ic macrophages due to a speciﬁc mechanism that among several other
factors also involves CD47. The blocking of CD47-SIRPα signal or the
loss of CD47 expression is one of the mechanisms that cause the re-
moval of non-aged erythrocytes from the bloodstream [51].
In order to identify potentialmembrane ligands ormediators for sol-
uble ﬁbrinogen binding, we addressed the involvement of the above
mentioned targets by using several different approaches that could
block the interaction of ﬁbrinogen to RBCs membrane. Strikingly, only
an antibody against human CD47 was able to signiﬁcant decrease theions of RBC were labeled with an anti-GPA antibody and ﬁbrinogen Alexa488 (Fib-
lexa488 plots; Total RBC (RBC_T) (A), Young RBC (RBC_Y) (B) and Old RBC (RBC_O)
h probe: Fib-Alexa488 or αGPA (PE). The third column (see αGPA (PE)/Fib-Alexa488
populations (RBC_T, RBC_Y and RBC_O) are double positive labelled. Additionally, in
ses the events dispersion due to an agglutination phenomenon that is responsible for
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Fig. 7. Analysis of ﬂow cytometry from RBC labelled with Fib-Alexa647 and/or antibody against CD47 conjugated with Phycoeryithrin (PE) (αCD47). RBC with different biological
ages (RBC-T, RBC-Y and RBC-O) were labelled with human soluble ﬁbrinogen conjugated with Alexa 647 (Fib-Alexa647) and αCD47 conjugated with PE (αCD47). (A) Flow cyto-
metry histograms for each RBC sample. No signiﬁcant differences in CD47 levels were found between the three RBC subpopulations. Notice that in the presence of anti-CD47 an-
tibody the soluble ﬁbrinogen interacts similarly with the three RBC populations, which suggests that this antibody is blocking the interaction of Fib-Alexa647 with the membrane of
younger RBC. (B) Analysis of geometric mean and median values. Signiﬁcant different values for geometric mean and median (*Pb0.01) are found between the interaction of sol-
uble ﬁbrinogen Alexa647 with young RBC and with old RBC. The RBC Fib-Alexa647 and RBC Fib-Alexa647+αCD47 were signiﬁcantly different (Pb0.05) for both parameters
analyzed.
489S. De Oliveira et al. / Biochimica et Biophysica Acta 1818 (2012) 481–490soluble ﬁbrinogen binding to RBCs. The ﬂuorescence confocal microsco-
py images also show us that the antibody against CD47 inhibits the in-
teraction between subpopulation of young and total RBCs and soluble
ﬁbrinogen, to a similar level obtained for the old RBCs subpopulation.
To better evaluate this we performed zeta-potential measurements by
using a similar approach recently published by Carvalho et al. [17].
Zeta-potential measurements can be used to determine the extension
of the interaction between two particles, by calculating the values of
Δζmax. Young RBCs have a higher extensive interaction with soluble ﬁ-
brinogen than the old ones. So we have determined the extension of
the interaction between pre-incubated RBCs with antibody against
CD47and human soluble ﬁbrinogen. The values obtained clearly show
us that the presence of the anti-CD47 antibody diminish the ability of
young RBCs to interact with ﬁbrinogen, Δζmax=(7.4±1.4) mV, this
value is signiﬁcantly (Pb0.001) higher than the values obtained for
young RBCs in the presence of anti-CD47, Δζmax=(3.5±0.8) mV, old
RBCs, Δζmax=(2.5±1.2) mV, and old RBCs in the presence of anti-
CD47, Δζmax=(2.4±1)mV. Additionally, as we did not ﬁnd signiﬁcant
differences in CD47 levels between the three subpopulations of RBCs
and as CD47 might have different conformations [48–51] it is tempting
to speculate that soluble ﬁbrinogen might interact more with younger
erythrocytes due to conformation changes of the protein that may
occur during the cell ageing process. Overall this set of experiments
seems to point out CD47 as a putative mediator for soluble ﬁbrinogen
interaction with human RBCs. Further experiments will be needed to
address with more accuracy if CD47 is just a putative mediator or if it
is playing a more important role in this speciﬁc interaction.Fig. 6. Fluorescence confocal microscopy of isolated human RBC. (A) Fluorescent confocal mi
ﬁbrinogen–Alexa647 (red signal). RBC subpopulations are referred as: Total (RBC-T), Young
tions present a positive labeling for ﬁbrinogen–Alexa 647, which are the RBC-T and RBC-Y.
the RBC-O subpopulation (scale bar=10 μm). (B) Fluorescent confocal microscopy of RBC
against CD47 conjugated with Phycoeryithrin (PE) (αCD47). We can observe that ﬁbrinog
presence of the anti-CD47 antibody seems to block the interaction of soluble ﬁbrinogen wiIn summary, we report here that soluble ﬁbrinogen speciﬁcally in-
teracts with the erythrocyte membrane in what it seems a non-
integrin like receptor, and we also conﬁrm that this interaction is age-
dependent. We also point out CD47 as a putative mediator for the solu-
ble ﬁbrinogen binding to human erythrocyte membrane. Knowing that
erythrocyte hyperaggregation promoted by high levels of ﬁbrinogen
may lead to severe and deathly scenarios in patients that suffers from
several diseases, we believe that this work has taken the initial steps
in order to use erythrocytes and CD47 as novel targets in the develop-
ment of new therapeutical strategies as an option to the already existing
ones that mainly target platelets and its receptors.
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Fig. 8. Variations of zeta-potential. The extension of the interaction between young
RBCs and soluble ﬁbrinogen was higher (Δζmax=(7.4±1.4) mV) than in any of the
other samples (RBC_Y_αCD47, Δζmax=(3.5±0.8) mV, RBC_O, Δζmax=(2.5±1.2)
mV, and RBC_O_αCD47, Δζmax=(2.4±1)). Statistically signiﬁcant differences
(Pb0.001) were found between the samples.
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